

Filed: 20 September 2001

PRELIMINARY AMENDMENT

(John

- (i) a biologically active agent which is able to produce an immune response in an animal to which it is administered;
  - (ii) a first material capable of forming particles; and
  - (iii) a polycationic carbohydrate according to claim 1.

C

 10. (Amended) A composition according to claim 9 wherein the chitin derivative is chitosan, chitosan chloride, or chitosan glutamate or a polycationic carbohydrate according to claim 2.

11. (Amended) A composition according to claim 6 wherein the particle comprises microspheres, microparticles or liposomes.

f


- 13. (Amended) A composition according to claim 6 wherein the first material is a polymeric material which has a molecular weight of 100kDa or more.
- 14. (Amended) A composition according to claim 6 wherein the first material comprises poly-(L-lactide).
- 15. (Amended) A composition according to claim 6 wherein the ratio of the first material to the polycationic carbohydrate is from 99:1 to 9:1 w/w.



Express Mail Label No. EL209599009US
U.S. National Phase Entry of PCT/GB00/01118
"Polycationic Carbohydrates as Immunostimulants in Vaccines"
Filed: 20 September 2001
PRELIMINARY AMENDMENT

Cost Ny 16. (Amended) A composition according to claim 6 wherein the biologically active agent is capable of generating a protective immune response against tetanus, diptheria,

or Yersinia pestis.



÷÷

- 18. (Amended) A composition according to claim 6 which is adapted for intranasal application.
- 19. (Amended) A composition according to claim 6 which is adapted for parenteral administration.
- 20. (Amended) A composition according to claim 6 which further comprises a chemical compound selected from
  - (A) a polyamino acid,
  - (B) a vitamin or vitamin derivative,
  - (C) cationic pluronics,
  - (D) a clathrate,
  - (E) a complexing agent,
  - (F) cetrimides,
  - (G) an S-layer protein, or
  - (H) methyl-glucamine.



Express Mail Label No. EL209599009US
U.S. National Phase Entry of PCT/GB00/01118
"Polycationic Carbohydrates as Immunostimulants in Vaccines"
Filed: 20 September 2001
PRELIMINARY AMENDMENT

ab

ζĦ

ĹΠ

N

Œ

23. (Amended) A method for producing a pharmaceutical composition, which method comprises encapsulating a biologically active agent in a first material, in the presence of a polycationic carbohydrate according to claim 1.

30. (Amended) A method of protecting an animal against a pathogen, said method comprising administering to said animal, a protective agent which is able to stimulate the animal's immune system to produce a response which is protective against said pathogen, and an immunostimulant comprising a polycationic carbohydrate according to claim 1.

- 31. (Amended) A method of protecting an animal against a pathogen, said method comprising administering to said animal, a protective agent which is able to stimulate the animal's immune system to produce a response which is protective against said pathogen, in the form of a composition according to claim 6.
- 32. (Amended) A method according to claim 30 wherein the protective agent which is able to stimulate the animal's immune system to produce a response which is protective against said pathogen, and an immunostimulant comprising a polycationic carbohydrate is applied parenterally or to a mucosal surface.

 Express Mail Label No. EL209599009US
U.S. National Phase Entry of PCT/GB00/01118
"Polycationic Carbohydrates as Immunostimulants in Vaccines"
Filed: 20 September 2001
PRELIMINARY AMENDMENT

0/8/

35. (Amended) The use of a polycationic carbohydrate or a pharmaceutically acceptable derivative thereof according to claim 1 as an immunostimulant, in the preparation of a vaccine for use in prophylactic or therapeutic treatment.

Respectfully submitted,

Dean W. Russell Reg. No. 33,452

KILPATRICK STOCKTON LLP 1100 Peachtree Street, Suite 2800 Atlanta, Georgia 30309 (404) 815-6528